Work for Sophiris Bio Inc.?
Claim Your Profile
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
Annual
Report
Sophiris Bio Inc. has reached its limit for free report views.
Sophiris Bio Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
Sophiris Bio Inc. is a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells.
